comparemela.com

Latest Breaking News On - Cust study - Page 1 : comparemela.com

GSK : Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial - Form 6-K -December 18, 2023 at 06:38 am EST

a1192x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER.

United kingdom generalUnited kingdomTreasure islandUnited statesCity ofJames dodwellTim foleyCamilla campbellJeff mclaughlinMick readeyDan smithHesham abdullahJosh williamsLyndsay meyerSteph mountifieldKathleen quinn

GSK : Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer - Form 6-K -October 30, 2023 at 07:13 am EDT

a6268r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER.

United kingdomUnited statesCity ofTreasure islandUnited kingdom generalNick stoneTim foleyCamilla campbellMick readeyJames dodwellSteph mountifieldKathleen quinnJeff mclaughlinLyndsay meyerDan smithJosh williams

GSK : European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer - Form 6-K

European Medicines Agency validates marketing authorisation application for Jemperli plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer . | April 25, 2023

United kingdom generalUnited kingdomUnited statesCity ofTreasure islandHesham abdullahSteph mountifieldDan smithKathleen quinnTim foleyJeff mclaughlinCamilla campbellJames dodwellMick readeyNick stoneJosh williams

AnaptysBio- and GSK-partnered immuno-oncology agent

Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting72% and 36% reduction.

United statesNick montemaranoDaniel fagaExchange commissionTesaro incEuropean society for medical oncologyInternational research on cancerStrategic communicationsAnaptysbio incKantar healthSociety of gynecologic oncologyThenew england journalEuropean societyMedical oncologyVirtual plenaryGynecologic oncology

US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer

/PRNewswire/ GSK plc (LSE/NYSE: GSK) today reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for.

City ofUnited kingdomUnited statesUnited kingdom generalHesham abdullahKathleen quinnDan smithCamilla campbellJosh williamsJeff mclaughlinMick readeyLyndsay meyerTim foleyJames dodwellSteph mountifieldNick stone

vimarsana © 2020. All Rights Reserved.